A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs AZD 5634 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Jan 2018 Planned End Date changed from 28 Feb 2018 to 14 Mar 2018.
- 10 Jan 2018 Planned primary completion date changed from 28 Feb 2018 to 14 Mar 2018.
- 11 Dec 2017 Planned End Date changed from 18 Jan 2018 to 28 Feb 2018.